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Abstract 
 
Background and objectives: Anemia in patients with chronic kidney disease (CKD) is related 
to a large extent to impaired erythropoietin (EPO) response, the timing and determinants of 
which remain unknown.  
Design, settings, participants, measurements: We measured EPO levels and studied their 
relations to glomerular filtration rates measured by 
51
Cr-EDTA renal clearance (mGFR) in 
336 all-stage CKD patients not receiving any erythropoiesis-stimulating agent.  
Results: In patients with WHO-defined anemia (hemoglobin (Hb) <13 (12) g/dL in men 
(women)), EPO response to Hb level varied by mGFR level: above 30 mL/min/1.73m², EPO 
and Hb levels were negatively correlated (r = -0.22, p=0.04), and when mGFR was less than 
30, they were not correlated (r = 0.09, p=0.3; p for interaction, 0.01). In patients with WHO-
defined anemia, the ratio of observed EPO to the level predicted by the equation for their Hb 
level decreased from 0.72 [0.57-0.95] for mGFR ≥ 60 mL/min/1.73m² to 0.36 [0.16-0.69] for 
mGFR < 15. Obesity, diabetes with nephropathy other than diabetic glomerulopathy, absolute 
iron deficiency, and high C-reactive protein concentrations were associated with increased 
EPO levels, independent of Hb and mGFR.  
Conclusions: Anemia in CKD is marked by an early relative EPO deficiency, but several 
factors besides Hb may persistently stimulate EPO synthesis. While EPO deficiency is 
probably the main determinant of anemia in patients with advanced CKD, in those with 
mGFR greater than 30 mL/min/1.73m², presence of anemia calls for other explicative factors. 
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Introduction  
Erythropoietin (EPO) was first isolated in 1971
1
 and its gene cloned in 1985.
2
 
Produced in the kidney and the liver, EPO stimulates the differentiation and proliferation of 
erythroid progenitors. The subsequent synthesis of recombinant human erythropoietin 
markedly changed the management of end stage renal disease (ESRD)-related anemia. Recent 
findings that erythropoiesis stimulating agents (ESA) did not improve cardiovascular and 
renal outcomes in patients with non-end-stage chronic kidney disease (CKD)
3
 
4
 
5
 have raised 
questions about the timing and degree of EPO deficiency in renal anemia.
6
 Our knowledge of 
the underlying cause of impaired EPO production is also incomplete. 
 Decrease in the endogenous EPO response to anemia, is thought to be one of the major 
mechanisms of CKD anemia. In subjects without CKD, EPO and Hb levels are negatively 
correlated, a feedback regulation that tends to be reversed in CKD patients.
7
 
8
 
9
 In ESRD 
patients, the feedback regulation process is blunted, even though it is somewhat preserved 
after hemorrhage
10
 
11
 and possibly at high altitudes.
12
 EPO levels remain in the normal range 
in CKD patients compared to non-anemic healthy controls.
7 13
 
14
 But for the degree of their 
anemia, CKD patients had EPO level lower than expected. The decrease in the endogenous 
EPO response to anemia has not been quantified in CKD patients, however. In addition, all 
studies conducted before 1980 used bioassays that provided higher EPO levels than those 
measured with present double-antibody sandwich immunoassays. Moreover, although 
inflammation and iron deprivation are well-documented risk factors for ESA resistance in 
dialysis patients, the determinants of EPO production have not been systematically studied in 
early-stage CKD.  
We therefore used reference methods to investigate the timing of EPO deficiency and 
its determinants according to renal function in 336 CKD patients. In those with anemia, we 
also quantified the endogenous EPO response to Hb decreases according to GFR level.  
 4 
 
Methods 
Study population  
The Nephrotest study is a prospective hospital-based cohort, enrolling adult patients with all 
CKD diagnoses, stages 1 through 5, not pregnant and not on dialysis or living with a kidney 
transplant.
15
 By the end of 2009, a total of 1294 patients had been referred to 2 physiology 
departments for work-ups to assess CKD progression and complications, including measured 
GFR (mGFR), according to standard methods. All patients provided written informed consent 
before inclusion in the cohort. In this study, we analyzed a subgroup of 336 patients who were 
receiving neither ESA nor intravenous iron and whose endogenous EPO was assayed. They 
did not differ from those without EPO measures for baseline age, gender, diabetes, median 
mGFR, or Hb level (data not shown). 
 
Information 
Demographic, clinical, and laboratory data were collected. Twenty-one percent of all patients 
had biopsy-proven nephropathy, but less than 10% of those with diabetes. Clinical criteria 
based on the presence of a history of albuminuria > 300 mg/g creatininuria and of another 
microangiopathy damage (retinopathy or/and neuropathy) were used to classify diabetic 
patients without renal biopsy as having diabetic glomerulopathy.  Other diabetic patients were 
classified as having other nephropathy types, most of them having probably a vascular 
nephropathy. We used Lipschitz's index
16
 to define iron status based on transferrin saturation 
(TSAT) and ferritin as follows: normal, TSAT ≥ 20%; TSAT < 20% and ferritin < 40 ng/mL, 
absolute iron deficiency; TSAT < 20% and ferritin ≥ 40 ng/mL, functional iron deficiency. 
We primarily used WHO sex-specific thresholds to define anemia: Hb concentration < 12 
g/dL for women and <13 g/dL for men. GFR was measured by renal clearance of 
51
Cr-EDTA 
 5 
as described earlier
17
 and categorized according to Kidney Disease Improving Global 
Outcomes guidelines.
18
  
 
Erythropoietin measurement and responsiveness to Hb level 
Endogenous EPO levels were determined in serum (100 µL) with the Quantitine IVD Epo 
double-antibody sandwich ELISA method from R&D Systems (Minneapolis, MN).  
To assess the response of endogenous EPO to Hb levels, we used a method previously 
developed and validated in non-CKD patients with anemia.
19
 
20
 
21
 We predicted the 
erythropoietin value for a given Hb level for all patients with WHO-defined anemia according 
to the following equation: predicted log10EPO (p-log10EPO) = 4.46 - (0.274 x Hb in g/dL), so 
that predicted EPO (p-EPO) =10
(p-logEPO)
 in IU/L.
19
  We then calculated the ratio of 
observed/predicted (O/P) EPO in these patients by dividing the observed endogenous EPO 
levels by those predicted by equation. Unlike others,
19
 however, we divided crude rather than 
log-transformed EPO values to express results as a percentage of EPO deficiency.  
 
Statistical analyses 
Because there were not normally distributed, EPO values were log-transformed in the 
analyses. The relations between EPO, Hb, and mGFR levels were studied in three steps. We 
first analyzed EPO response to decreased Hb according to mGFR level, independent of 
anemia status. For this purpose, we assessed the correlation between Hb and log10EPO and 
tested the interactions with renal function level for different mGFR thresholds: 15, 30, and 45 
mL/min/1.73m². We then studied the correlations between endogenous EPO and Hb levels 
according to WHO-defined anemia status and mGFR in 2 classes, < or ≥ 30 mL/min/1.73m². 
Finally, we studied Pearson correlations between EPO and mGFR in anemic and non anemic 
 6 
patients. In a sensitivity analysis, we repeated this step after classifying patients according to 
anemia defined with only one cut-off value of 12 g/dL irrespective of sex.  
Other factors associated with EPO levels were first studied with bivariate analyses that 
used Kruskal-Wallis correlations for qualitative and Pearson correlations for quantitative 
variables. Interactions with mGFR, anemia status, or sex in the relations between the studied 
factors and EPO level were systematically tested. We then conducted a multivariate 
regression analysis of determinants of EPO levels, using three nested models that we 
compared according to maximum likelihood criteria. Model 1 included age in years, center, 
and a combined variable derived from previous step findings: no anemia, anemia and mGFR 
≥30 mL/min/1.73m², anemia and mGFR <30. Models 2 and 3 sequentially added other risk 
factors identified from the bivariate analysis, namely BMI and diabetes with glomerular or 
other types of nephropathy in model 2, and iron index and CRP in model 3. We studied 
log10EPO and expressed the results in percentage of EPO change in the exposed compared 
with the reference category. All analyses were performed with SAS 9.1 (SAS Institute, Cary, 
NC).  
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Results 
Patient characteristics 
Mean age was close to 60 years, and patients were predominantly men and of European origin 
(Table 1). Vascular nephropathy was the most common type of CKD. Two thirds of the 
patients had CKD stage 3B or 4. WHO-defined anemia (Hb <13 (12) g/dL in men (women)) 
was present in 55% of men and 63% of women. EPO levels ranged from 1.9 to 47.8 IU/L.  
 
Relations between erythropoietin, hemoglobin, and measured GFR levels 
Endogenous EPO response to Hb level varied according to mGFR level. The strongest 
interaction between Hb and mGFR in the relation with EPO was observed for an mGFR 
threshold of 30 mL/min/1.73 m² (p for interaction=0.01); interaction was not statistically 
significant for mGFR of 45 and 15 mL/min/1.73m² (p=0.72 and 0.18). EPO and Hb levels 
were negatively correlated (r = -0.2, p=0.04) in patients with mGFR value ≥ 30 
mL/min/1.73m², but were not when mGFR level was < 30 (r = 0.07, p=0.3). Analysis by 
anemia status, however, showed that this pattern was limited to patients with anemia (Figure 
1).  
Moreover, there was no correlation between EPO and mGFR levels in patients with or 
without anemia (r = 0.08 and 0.01, respectively, both ns). In anemic patients, predicted EPO 
value was always consistently greater than observed EPO at all mGFR (Figure 2). The 
observed to predicted (O/P) EPO ratio fell markedly with mGFR decline from 0.72 [0.57-
0.95] for mGFR ≥ 60 mL/min/1.73m² to 0.36 [0.16-0.69] for mGFR < 15, the relative EPO 
deficits ranging so from 28 to 64% from CKD stages 1-2 to 5. 
 
Other factors associated with erythropoietin level 
EPO was significantly higher in patients aged 60 to 69 years, in those overweight or obese, or 
with absolute iron deficiency, diabetes with nephropathy other than diabetic glomerulopathy, 
 8 
or C-reactive protein (CRP) > 8 mg/L, compared with their counterparts without these 
conditions (Table 2). EPO levels were not related to gender, geographic origin, treatment with 
renin angiotensin system  inhibitors, or urine protein to creatinine ratio, vitamin D or folate 
levels. There was a significant interaction (p = 0.04) between serum albumin and mGFR: 
higher EPO levels with lower albumin values were observed only in patients with mGFR ≥ 
30 mL/min/1.73 m². No other significant interaction was seen with mGFR, gender, or anemia 
(all p ≥ 0.2). Mean Hb level was significantly higher in patients overweight or obese than in 
those with normal BMI, 12.6 ± 1.5 g/dL vs 12.2 ± 1.3 g/dL (p=0.03), but did not significantly 
differ with CRP level ≤  or > 8 mg/L, 12.5 ± 1.5 g/dL vs 12.1 ± 1.5 g/dL (p=0.1).  
 
Multivariate analysis of factors associated with change in erythropoietin levels 
In view of the observed interaction between mGFR and anemia status, we created a combined 
variable for multivariate analyses (Table 3). After adjusting for covariates, EPO levels were 
17.3% higher in patients with WHO-defined anemia and mGFR ≥ 30 mL/min/m² than in the 
reference group without anemia, whereas they were similar in those with anemia and mGFR < 
30 mL/min/1.73m² (Table 3). The fully-adjusted EPO increase was associated with 
overweight, obesity, diabetes with nephropathy types other than diabetic glomerulopathy, 
absolute iron deficiency, and CRP > 8 mg/L and ranged from 22 to 55%. Including these 
variables significantly improved the log likelihood of the fully-adjusted model compared to 
that with anemia and mGFR alone to explain EPO changes. Serum albumin and EPO levels 
were no longer associated after adjusting for the covariates. Similar results were obtained 
throughout the analysis when using a unique cut-off value of 12 g/dL for both genders. EPO 
level for patients with anemia and mGFR ≥ 30 mL/min/1.73m² was 13% higher than in those 
without anemia (p=0.04), and relations with other factors were unchanged. 
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Discussion  
This study confirms the existence of an interaction between hemoglobin, GFR and 
erythropoietin in non-end-stage CKD, but its contribution and novelty lie in four key points. 
First, in contrast with earlier studies, the analysis was conducted by anemia status, which 
enabled to show that there was no relation between EPO concentration and mGFR levels in 
patients without anemia, whereas EPO deficiency increases with mGFR decline in anemic 
patients. Second, the most original findings indicate that several factors other than Hb and 
GFR levels may stimulate EPO production in CKD. Third, this study also quantified the 
relative EPO deficiency throughout the range of mGFR pointing out its importance as early as 
stages 1-2 that worsens as mGFR declines to reach 64% at stage 5. Finally, the quality of 
patient phenotype, both regarding GFR and EPO measurements resulted in a most accurate 
assessment of the EPO deficiency in non end-stage CKD.  
In both normal and disease conditions, serum EPO must be interpreted according to 
Hb level.
8
 Under non-anemic conditions, there is no need for higher EPO since Hb 
concentration and oxygen supply to tissues is still sufficient. In contrast, in patients with 
anemia, serum EPO is expected to be inversely correlated with Hb, as a result of the feedback 
process described in the introduction.
7 8
 Impairment of this physiological feedback process in 
CKD was first described in dialysis patients.
7
 Fehr et al. first suggested that it began below a 
GFR of 40 mL/min/1.73m², but did not stratified the analysis by anemia status.
9
 Here, we 
studied the interaction between Hb and GFR according to anemia status and found a slightly 
lower GFR threshold in patients with anemia, at 30 mL/min/1.73m², probably explained by 
their use of Cockcroft-Gault estimated GFR while we used measured GFR.  
We further showed that despite very early relative EPO deficiency in the course of 
CKD, physiological response to anemia was somewhat preserved in patients with GFR above 
30 mL/min/1.73m². Conversely, below 30 mL/min/1.73m², patients with anemia had severe 
 10 
EPO deficiency, with lower EPO levels than patients without anemia. At this stage, declining 
EPO concentration is likely to explain a major part of CKD anemia.  
Beyond Hb and mGFR levels, a number of other factors were related to EPO 
concentration. First, we found absolute iron deficiency was associated with an increased EPO 
level. This association has previously been described in non-CKD patients and in dialysis 
patients.
22
 
23
 
24
 
25
 It was also expected based on recent findings about the involvement of EPO 
in iron metabolism and particularly about hepcidin.
26
 EPO reduces circulating hepcidin in 
humans
27
 and directly affects the intestinal handling of iron in rat models.
 28
 Inversely, 
absolute iron deficiency is associated with increased EPO levels and early blockage of 
erythroid differentiation.
29
 Transferrin receptor 2 (TfR2), recently described as a sensor of 
body iron levels, may mediate EPO change with absolute iron deficiency.
30
  
Interestingly, diabetes with nephropathy other than diabetic glomerulopathy was 
associated with enhanced EPO production, while diabetic glomerulopathy was not. To the 
best of our knowledge, this finding is new and requires confirmation by others. In contrast, 
other authors
31
 
32
 suggest that EPO response may be blunted in diabetic patients with 
microangiopathy, thus explaining their higher rate of anemia compared to non diabetic 
patients. Although we previously described such a higher rate of anemia, our findings here do 
not support this hypothesis, as EPO levels did not differ between patients with diabetic 
glomerulopathy and those without diabetes. 
Another novel finding is that higher EPO levels were associated with increasing BMI. 
Several studies have shown no excess risk of anemia in patients with obesity despite increased 
inflammation and functional iron deficiency related to the hepcidin increase.
15  33 34 
 We have 
previously described a 40% lower risk of anemia in obese patients in the NephroTest cohort.
15
  
This apparently protective effect of obesity on anemia may result from the positive relation 
we observed between BMI and EPO levels. Further research is needed to investigate whether 
 11 
sleep apnea syndrome and its consequence, the chronic hypoxia common in obese patients, is 
a plausible trigger for the EPO increase. 
Finally, we found a positive association between inflammation and EPO level, 
independent of Hb and mGFR levels. Wagner et al recently found the same association in 
diabetic patients with CKD.
35
 Experimentally, it is well established that EPO production is 
down-regulated by some cytokines that also influence EPO action.
36
 
37
 
38
In clinical studies, 
however, patients with chronic inflammation have preserved EPO feedback to changes in 
their Hb level.
39
 
40
 
41
 Their EPO level is somewhat less stimulated than it is in the presence of 
absolute iron deficiency, which has the strongest impact on EPO production. Of note both 
Wagner and our results suggest a stimulatory role of inflammation on EPO independent of Hb 
level. It is likely that the variations of the different pro- and anti-inflammatory cytokines are 
far from explaining the variations in EPO levels. Other pro-ischemic factors may participate 
in EPO stimulation. 
The major strengths of our study include its large sample size of well-phenotyped 
patients with a wide range of renal function and types of kidney disease compared with 
previous studies, and its use of measured GFR. Misclassification of patients according to renal 
function is therefore unlikely. This study also had the power to analyze a number of 
determinants and to test potential interactions with renal function in their relation with EPO, 
which has facilitated understanding of the underlying mechanisms. The higher number of men 
than women in this cohort reflects the well-established higher risk for CKD in men, but the 
lack of interaction with gender in the studied associations allows generalizability of the results 
to both genders. This study however has limitations, mainly related to its cross-sectional 
design that prevents causal inferences. For example, whether EPO deficiency precedes 
decreased Hb and causes anemia in the early stage of CKD or whether Hb decline is caused 
by other mechanisms and is insufficiently corrected by EPO cannot be answered. Because the 
 12 
EPO level was measured only once for each patient, the robustness of the correlations may be 
affected by the inter-assay variability of the EPO level within any individual. This study 
clearly showed, however, distinct patterns of relations between EPO and Hb levels according 
to whether mGFR was < or ≥ 30 mL/min/1.73 m2. This interaction suggests that EPO plays a 
role in different phases of CKD anemia. Similarly, the association between EPO levels and 
the other factors we studied should be interpreted with caution. Nonetheless, the absence of 
interaction between these factors and mGFR, in contrast to Hb, suggests that these factors 
have a persistent impact on EPO level throughout the range of mGFR.  
Altogether, our findings may shed some light on the surprising and disappointing 
results from recent ESA trials, particularly the Trial to Reduce Cardiovascular Events with 
Aranesp Therapy
5 
 conducted in diabetic CKD patients. The higher EPO production found in 
our study associated with diabetes with nephropathy types other than diabetic glomerulopathy 
may be a missing link. These patients may predominantly have a vascular nephropathy and 
have enhanced EPO levels, despite their similar anemia rates.
15
 This finding suggests 
resistance to EPO, which has recently been linked to mortality.
42
 ESA should thus be 
administered cautiously to patients with enhanced EPO concentration, as they may benefit 
less and experience more adverse effects. Endogenous EPO response to anemia may bring 
new perspectives in the assessment of the potential benefit of an ESA prescription.    
In conclusion, CKD anemia is associated with an early relative EPO deficiency, that 
rises from 28 to 64% as renal function declines. In patients with mGFR greater than 30 
mL/min/1.73m², presence of anemia calls for explicative factors other than EPO deficiency, 
while it is probably the main determinant of anemia in patients with advanced CKD. But 
several factors besides Hb may stimulate EPO synthesis, bringing a more complex view of  
EPO response to Hb decrease in CKD population.  
 13 
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 Table 1 - Patient characteristics  
 
 Mean±SD 
Median [IQR] 
% (n) 
N 336 
Age 58.8 ± 14.6 
Men  73 (246)  
African origin 7.4 (25) 
Diabetes   
With diabetic glomerulopathy 13.6 (46) 
With other nephropathy types 12.8 (43) 
Kidney disease  
Diabetic nephropathy 13.6 (46) 
Glomerular nephropathy 16.9 (57) 
Vascular nephropathy 27.8 (94) 
Polycystic kidney disease 2.3 (8) 
Interstitial nephritis 9.5 (32) 
Unknown 29.4 (99) 
Body mass index (kg/m²) 26.1 ± 4.2 
mGFR mL/min/1.73m² 33.6 [22.9-46.1] 
≥ 60 10.4 (35) 
45- 60  15.4 (52) 
30- 45  34.8 (117) 
15 -30  30.6 (103) 
<15  8.6 (29) 
PCR (mg/mmol) 45.3 [17.7-142.5] 
Serum albumin (g/L) 40.2 ± 5.2 
Hemoglobin  (g/dL) 
                Men 
                 Women 
12.4 ± 1.4 
12.7 ± 1.4 
11.6 ± 1.3 
EPO (IU/L ) 9.1 [6.7-13.01] 
Oral iron therapy 12.8 (43) 
ACEI/ARBs 78.8 (265) 
BMI=body mass index; mGFR=glomerular filtration rate measured by 51Cr-EDTA renal clearance; PCR=ratio of urinary 
protein to creatinine; EPO= measured erythropoietin; ACEI/ARBs= Angiotensin Converting Enzyme Inhibitors/Angiotensin 
Receptor Blockers  
Table 2: Crude analysis of factors associated with erythropoietin levels 
  
N 
EPO (UI/ml) 
median [IQR] 
 
p  
Gender men 
              women 
245 
91 
9.3 [6.7-13.5] 
8.9 [6.7-11.9] 
 
0.2 
Age (years)              < 50  
[50-59[  
[60-69[ 
[70-max[ 
91 
76 
73 
96 
8.5 [5.7-11.5] 
8.9 [6.9-11.6] 
10.5 [7.2-16.1] ** 
9.2 [7.0-12.7] 
 
0.01 
African origin     no 
                            yes 
296 
25 
8.9 [6.7-12.6] 
9.9 [6.1-13.6] 
 
0.3 
Body mass index 
(kg/m²)    
< 25 
[25-30[  
[30-max[ 
136 
138 
62 
8.6 [5.9-11.4] 
9.3 [6.7-13.1] * 
10.6 [7.6-15.7] *** 
 
0.005 
Diabetes 
No  
With diabetic glomerulopathy   
With other nephropathy types 
 
 
247 
46 
43 
 
8.8 [6.1-12.2] 
8.6 [6.8-12.1] 
11.4 [8.7-16.2] ***  
 
0.002 
Iron Index          
Normal 
Absolute iron deficiency 
Functional iron deficiency 
 
253 
16 
67 
 
8.9 [6.3-12.7] 
14.9 [9.0-19.8] ** 
8.9 [7.0-11.8] 
 
 
0.02 
CRP ≤ 8 g/L 
         > 8 g/L 
289 
40 
8.9 [6.3-12.7] 
10.8 [7.7-14.6] 
 
0.006 
Serum albumin  (g/L) 
in patient with mGFR ≥ 30 mL/min/1.73 m² 
         ≥ 40   
         < 40   
in patients with mGFR < 30 mL/min/1.73m² 
          ≥ 40   
          < 40  
 
 
124 
80 
 
61 
71 
 
 
8.5 [5.9-12.6] 
10.9 [7.6-14.0] 
 
9.4 [6.5-13.0] 
8.3 [6.3-12.2] 
 
 
 
0.003 
 
 
0.6 
PCR (mg/mmoL) < 30 
[30-300[ 
[300-max[ 
140 
165 
31 
8.9 [5.9-12.7] 
9.8 [7.05-13.5] 
7.6 [6.1-10.5] 
 
0.2 
PTH (pg/mL) 
  
< 60  
         ≥ 60  
145 
191 
8.9 [6.7-11.9] 
9.2 [6.7-14.1] 
0.3 
1-25OH2Vitamin D 
(pg/mL)   
< 20 
≥ 20   
214 
121 
9.6 [7.0-13.5] 
8.7 [5.6-11.8] 
 
0.09 
Folates (ng/mL) 
 
< 8  
≥ 8 
141 
175 
9.4 [6.7-15.4] 
8.9 [6.2-12.4] 
 
0.5 
ACEI/ ARBs      no 
                            yes 
71 
265 
9.4 [7.1-12.0] 
8.9 [6.5-13.2] 
 
0.6 
* p < 0.05; ** p< 0.01; ***p < 0.001;  
mGFR=glomerular filtration rate measured by 51Cr-EDTA renal clearance; Iron index: TSAT ≥ 20% normal iron profile; 
TSAT<20% and ferritin < 40 ng/mL absolute iron deficiency; TSAT < 20% and ferritin ≥ 40 ng/mL functional iron 
deficiency; CRP=C reactive protein; BMI=body mass index; PCR=ratio of urinary protein to creatinine; PTH=parathyroid 
hormone; ACEI/ARBs= angiotensin-converting enzyme inhibitors/angiotensin receptor blockers   
Table 3: Multivariate analysis of factors associated with erythropoietin levels in 336 patients  
 
 
 Model 1 
 
Model 2 
 
Model 3 
 
% change    p        p-LRT % change   p           p-LRT % change    p           p-LRT 
Anemia*mGFR status          
No anemia  Ref - 0.10 Ref - 0.03 Ref - 0.05 
Anemia and mGFR ≥ 30  15.7 0.04 20.1 0.01 17.3 0.03 
Anemia and mGFR < 30 0.3 0.9 2.6 0.7 0.0 0.9 
Body mass index (kg/m²)                              < 25  
           [25-30[ 
 ≥30  
 Ref 
15.3 
29.8 
- 
0.03 
0.002 
0.008 Ref 
15.8 
30.5 
- 
0.02 
0.001 
0.005 
Diabetes     No  
  With diabetic glomerulopathy   
  With other nephropathy types 
 Ref 
-6.4 
23.8 
- 
0.4 
0.02 
0.03 Ref 
-5.5 
26.0 
- 
0.5 
0.01 
0.01 
Iron Index         Normal 
               Absolute iron deficiency 
               Functional iron deficiency 
  Ref 
55.2 
-0.1 
- 
0.001 
0.9 
0.006 
CRP                                          ≤ 8 mg/L 
                                    > 8 mg/L 
  Ref 
21.8 
- 
0.03 
0.02 
Log likelihood 1.05 9.6 
P< 0.01versus Model 1 
19.0 
P<0.001 versus Model 1 
 
Model 1, adjusted for age in years, centre (ns), combined variable anemia*mGFR status; model 2  adjusted for age in years, centre (ns), combined variable anemia*mGFR status, body mass 
index, diabetes; Model 3 adjusted for age in years, centre (ns), combined variable anemia*mGFR status, body mass index, diabetes, iron index, C Reactiv Protein 
p is the p-value of each category compared with the reference category; p-LRT is the p-value of the variable in the model 
mGFR=glomerular filtration rate measured by 
51
Cr-EDTA renal clearance; BMI=body mass index; CRP=C reactive protein; Iron index: TSAT ≥ 20% normal iron profile; 
TSAT<20% and ferritin < 40 ng/mL absolute iron deficiency; TSAT < 20% and ferritin ≥ 40 ng/mL functional iron deficiency;
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Figure 1 – Relations between EPO (log10) and hemoglobin level by WHO-defined anemia 
status and mGFR level. Open circles: non anemic patients, solid circles: anemic patients
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Figure 2. Observed and predicted erythropoietin by mGFR levels in patients with WHO-
defined anemia. 
 
  
